美国医疗折扣服务商GoodRx Holdings, Inc.近日宣布推出针对自保型雇主的创新补贴方案。通过该计划，企业可为员工报销礼来公司生产的减肥注射笔Zepbound Kwikpen的部分费用，使患者实际支付金额接近GoodRx平台标注的449美元优惠价。
这一举措将帮助自保雇主在控制医疗成本的同时，为员工提供更易负担的减肥治疗方案。Zepbound作为礼来公司推出的新型GLP-1受体激动剂，其标准市场零售价通常超过1000美元，而通过GoodRx的补贴机制，员工自付费用将大幅降低。
业内分析指出，此举有望提升GoodRx在企业健康福利领域的市场份额，同时为礼来公司拓展Zepbound的市场渗透率提供新路径。目前该补贴计划已面向全美自保雇主开放申请，企业可根据员工需求灵活设定补贴额度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.